Acalabrutinib is a selective BTK inhibitor that blocks B-cell receptor signalling, thereby inhibiting the growth and survival of malignant B-cells.
Recommended for:
ACALNIB is taken orally as prescribed, typically twice daily. Capsules should be swallowed whole with water, with or without food. Duration and dose are individualised based on clinical response and tolerance.
Contraindications
Side effects